NASDAQ
03.10.25 | 21:59
13,350 US-Dollar
-0,07 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Arcus Biosciences auf Morgan-Stanley-Konferenz: Strategische Prioritäten bis 2026 | - | Investing.com Deutsch | ||
| 09.09. | Arcus Biosciences: Strategische Positionierung im Markt für Nierenzellkarzinome | 2 | Investing.com Deutsch | ||
| 18.08. | Mizuho raises Arcus Biosciences stock price target on casdatifan potential | 2 | Investing.com | ||
| 06.08. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.07. | Arcus Biosciences' cancer drug gets orphan drug status | 1 | Seeking Alpha | ||
| 10.07. | Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer | - | RTTNews | ||
| 08.07. | Arcus Biosciences February 2025 slides: oncology pipeline progresses despite Q1 miss | 3 | Investing.com | ||
| 01.07. | Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment | 1 | Insider Monkey | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 12.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.06. | H.C. Wainwright bekräftigt Kaufempfehlung für Arcus Biosciences-Aktie | 1 | Investing.com Deutsch | ||
| 02.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | Forecasting The Future: 5 Analyst Projections For Arcus Biosciences | 2 | Benzinga.com | ||
| 06.11.24 | Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update | 368 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
| 09.10.24 | Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium | 684 | Business Wire | Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in an oral plenary session by Dr. Toni Choueiri... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 1,311 | +1,86 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 16,895 | -0,56 % | Figma, Beam, Intellia: Cathie Wood setzt auf riskante (Bio-)Tech-Aktien | Die bekannte US-Investorin Cathie Wood blieb ihrer Linie auch im August 2025 treu und griff wieder einmal beherzt bei spekulativen Tech- und Biotech-Werten zu. Mit ihrem wichtigsten Fonds, dem ARK Innovation... ► Artikel lesen | |
| XOMA ROYALTY | 34,200 | +1,18 % | XOMA Royalty Corporation Extends Tender Offer to Acquire LAVA Therapeutics N.V. | EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) and LAVA Therapeutics N.V. ("LAVA") (Nasdaq:... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,796 | +1,29 % | Telix Pharmaceuticals Limited: Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis | MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,760 | +0,66 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| CYTOKINETICS | 48,600 | +0,83 % | Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? | ||
| ROCKET PHARMACEUTICALS | 2,717 | +1,04 % | Rocket Pharmaceuticals meldet Rücktritt von Vorstandsmitglied Pedro Granadillo | ||
| OUTLOOK THERAPEUTICS | 0,917 | -0,97 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Provides Update on Type A Meeting with FDA | ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,460 | -0,89 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration | WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with... ► Artikel lesen | |
| ROIVANT SCIENCES | 13,630 | -0,26 % | Roivant Sciences files shelf registration for potential securities offerings | ||
| CARTESIAN THERAPEUTICS | 8,950 | +7,19 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grant | FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| ANNOVIS BIO | 1,860 | -0,85 % | Canaccord Genuity reaffirms Buy rating on Annovis Bio stock | ||
| ADVERUM BIOTECHNOLOGIES | 4,400 | -4,76 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 1,675 | +1,82 % | Quince Therapeutics: Citizens bestätigt "Market Outperform"-Rating mit Kursziel von 8 US-Dollar | ||
| VERA THERAPEUTICS | 30,130 | +3,22 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen |
Das Unternehmen ARCUS BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,07 %) liegt der Kurs bei 13,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.